Bioshares Biotech Summit Presentation
Filed with ASX · · 52 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
- Becoming a substantial holder
- Notification regarding unquoted securities - CU6
- SECuRE update
- Ceasing to be a substantial holder
Later from Clarity Pharmaceuticals
- Preliminary Final Report
- Date of Annual General Meeting 25 November 2026
- Annual Report to shareholders
- Appendix 4G
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals